Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Dániel Szili, Marcell Cserhalmi, Zsuzsanna Bankó, György Nagy, David E Szymkowski & Gabriella Sármay. (2014) Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19. mAbs 6:4, pages 991-999.
Read now
Read now
Shawn Shetty & A. R. Ahmed. (2013) Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 46:8, pages 487-496.
Read now
Read now
Annika Deiß, Isabel Brecht, Axel Haarmann & Mathias Buttmann. (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Review of Neurotherapeutics 13:3, pages 313-335.
Read now
Read now
Articles from other publishers (12)
Lara D Veeken, Merel A A Opdam, Lise M Verhoef, Calin Popa, Reinout van Crevel & Alfons A den Broeder. (2023) Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study. Rheumatology.
Crossref
Crossref
Merel A A Opdam, J H de Leijer, Nathan den Broeder, Rogier M Thurlings, Wilfred van der Weele, Michael T Nurmohamed, Marc R Kok, Lenny van Bon, David F Ten Cate, Lise M Verhoef & Alfons A den Broeder. (2023) Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. Rheumatology 62:1, pages 330-334.
Crossref
Crossref
Juan Luis Chico-García, Fernando Rodríguez-Jorge, Raquel Sainz-Amo, Enric Monreal, Paulette Walo-Delgado, Ernesto Roldán, Eulalia Rodríguez-Martín, Jaime Masjuan, Lucienne Costa-Frossard, Susana Sainz de la Maza & Luisa Maria Villar. (2022) B-lymphocyte-guided retreatment contributes to establish good effectiveness and safety profile in MS patients treated with rituximab. Multiple Sclerosis and Related Disorders 68, pages 104218.
Crossref
Crossref
Gerasimos Evangelatos, George E Fragoulis, Kalliopi Klavdianou, Melina Moschopoulou, Dimitrios Vassilopoulos & Alexios Iliopoulos. (2021) Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience. Rheumatology 60:5, pages 2375-2382.
Crossref
Crossref
Chiara Caraccio, Sachi Krishna, Darci J. Phillips & Christian M. Schürch. (2020) Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. Frontiers in Immunology 11.
Crossref
Crossref
Yuhong Shi, Yanbin Wu, Yafei Ren, Yanan Jiang & Yiqiang Chen. (2019) Infection risks of rituximab versus non‐rituximab treatment for rheumatoid arthritis: A systematic review and meta‐analysis. International Journal of Rheumatic Diseases.
Crossref
Crossref
Lucía Silva-Fernández, Diederik De Cock, Mark Lunt, Audrey S Low, Kath D Watson, Deborah P M Symmons & Kimme L Hyrich. (2018) Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology 57:9, pages 1533-1540.
Crossref
Crossref
Leslie R. Harrold, George W. Reed, Chitra Karki, Robert Magner, Ashwini Shewade, Ani John, Joel M. Kremer & Jeffrey D. Greenberg. (2016) Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry. Arthritis Care & Research 68:12, pages 1888-1893.
Crossref
Crossref
H.-Christian von Büdingen, Arumugam Palanichamy, Klaus Lehmann-Horn, Brady A. Michel & Scott S. Zamvil. (2015) Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets. European Neurology 73:3-4, pages 238-246.
Crossref
Crossref
Seung Y. Chu, Karen Yeter, Roshan Kotha, Erik Pong, Yvonne Miranda, Sheryl Phung, Hsing Chen, Sung-Hyung Lee, Irene Leung, Christine Bonzon, John R. Desjarlais, William Stohl & David E. Szymkowski. (2014) Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor. Arthritis & Rheumatology 66:5, pages 1153-1164.
Crossref
Crossref
Fabiola Atzeni, Maurizio Benucci, Salvatore Sallì, Sara Bongiovanni, Laura Boccassini & Piercarlo Sarzi-Puttini. (2013) Different effects of biological drugs in rheumatoid arthritis. Autoimmunity Reviews 12:5, pages 575-579.
Crossref
Crossref
Dirk Nagorsen, Peter Kufer, Patrick A. Baeuerle & Ralf Bargou. (2012) Blinatumomab: A historical perspective. Pharmacology & Therapeutics 136:3, pages 334-342.
Crossref
Crossref